HCA Healthcare (NASDAQ:HCA) disclosed a series of insider transactions involving Erica Rossitto, the company's SVP & Chief Nurse Executive, according to filings dated November 10, 2026. The disclosures detail a sale of common stock, an exercise of stock appreciation rights, and a share disposal tied to tax obligations, all occurring within a four-day window.
Sale of Common Stock
On November 10, 2026, Rossitto sold 3,500 shares of HCA common stock at a price of $505.8101 per share, generating total proceeds of $1,770,335. The transaction reduced her direct holdings in the healthcare provider.
Exercise of Stock Appreciation Rights
Earlier, on November 6, 2026, Rossitto acquired 13,120 shares of HCA common stock through the exercise of stock appreciation rights. The acquisitions were executed at prices ranging from $81.96 to $101.16 per share, for a total value of $1,172,083. The stock appreciation rights had vested in annual installments beginning in February 2018 and January 2019, indicating a multi-year vesting schedule.
Tax Withholding Disposal
Also on November 6, 2026, Rossitto disposed of 6,601 shares of HCA common stock at a price of $494.99 per share, valued at $3,267,428. The disposal was made to satisfy tax withholding obligations associated with the exercise of stock appreciation rights, a common practice among executives to cover tax liabilities without additional cash outlay.
Post-Transaction Holdings
Following these transactions, Rossitto directly holds 13,426 shares of HCA Healthcare common stock, as reported in the filing.
Recent Financial Performance
In other recent news, HCA Healthcare reported stronger-than-expected third-quarter 2026 results. The company posted adjusted earnings of $7.22 per share, surpassing Wall Street's forecast of $6.65. Revenue also exceeded expectations, coming in at $19.85 billion compared to the anticipated $19.33 billion.
Despite these positive figures, investors appeared cautious due to concerns over exchange-related volume losses and a softer earnings outlook for 2027. HCA's management indicated that 2027 earnings are expected to be consistent with those of 2026, which may have dampened enthusiasm for the recent earnings beat.
BofA Securities responded to HCA's solid execution by raising its price target for the company from $450 to $500 while maintaining a Neutral rating. This adjustment reflects anticipated benefits from supplemental Medicaid programs.
HCA continues to experience growth, with same-facility adjusted admissions rising 2.7% and emergency room visits increasing by 5.1%.
Market Context
Shares of HCA closed at $504.42 on the day of the sale, down $0.47 or 0.09%, and traded at $502.22 after hours, down $2.20 or 0.44%. The stock has traded in a range that reflects investor reaction to the mixed earnings outlook and insider activity.
The disclosed transactions provide insight into executive compensation realization and personal portfolio management. The exercise of stock appreciation rights at prices significantly below the current market price generated a substantial paper gain, while the subsequent sale and tax-related disposal converted a portion of that gain into cash and covered associated tax liabilities.
Investors and analysts often monitor insider transactions for signals about management's confidence and valuation perceptions. However, such transactions can also be driven by diversification, liquidity needs, or tax planning, and may not necessarily reflect a directional view on the company's prospects.
HCA Healthcare remains a prominent player in the Healthcare Providers & Services industry, and its recent quarterly performance, combined with analyst actions and insider activity, continues to draw attention from market participants.